![futuristic image of human brain](https://pro.campus.sanofi/.imaging/mte/portal/3840/dam/Portal/UK/Articles/Neurology/multiple-sclerosis-article/page_muliple-sclerosis_banner.jpg/jcr:content/page_muliple-sclerosis_banner.jpg)
Multiple Sclerosis
Sanofi's history in MS
This website contains promotional content and is intended for Healthcare Professionals based in the United Kingdom only. Some content is only relevant to HCPs practising in Great Britain (England, Scotland, Wales). This website is optimised for desktop use, and some features may perform differently on mobile devices.
Sanofi's history in MS
Explore the advancement of Fabry disease expertise and dissemination of real-world evidence to the Fabry community.
Find out more about the safety and tolerability profile for Fabrazyme®.
Explore the results and evidence supporting Fabrazyme® and how it was studied through several clinical trials.
Find out more about the safety and tolerability profile for Nexviadyme®.
Explore the results and evidence supporting Nexviadyme® and how it was studied through several clinical trials.
Sanofi is working to harness this modern technology to strengthen understanding and diagnostic outcomes for those living with a rare disease.
A hub for healthcare professionals to discover and find information on our medicines and therapies
MAT-XU-2305061 (v2.0) Date of preparation: February 2024